| Description | ICA (N-[4-(2-Pyridinyl)-2-thiazolyl]-2-pyridinamine) is a SK channel inhibitor and exhibits antileishmanial activity (IC50: 2.1 µM). |
| In vitro | ICA prevents electrically induced runs of atrial fibrillation in the isolated right atrium and induces atrial postrepolarization refractoriness and depolarizes resting membrane potential. SK channel inhibition by ICA (10-30 μM) demonstrates prominent depression of other sodium channel-dependent parameters, at increased pacing frequencies. The SK channel inhibitor ICA shows antiarrhythmic effects. ICA at 1 to 10 μM displays conduction velocity[2]. |
| Target activity | Leishmania tropica:2.1 μM |
| Synonyms | N-[4-(2-Pyridinyl)-2-thiazolyl]-2-pyridinamine |
| molecular weight | 254.31 |
| Molecular formula | C13H10N4S |
| CAS | 3374-88-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 60 mg/mL (235.93 mM), Sonication is recommended. |
| References | 1. Bhuniya D, et al. Aminothiazoles: Hit to lead development to identify antileishmanial agents. Eur J Med Chem. 2015 Sep 18;102:582-93. 2. Skibsbye L, et al. Antiarrhythmic Mechanisms of SK Channel Inhibition in the Rat Atrium. J Cardiovasc Pharmacol. 2015 Aug;66(2):165-76. |